InMed Pharmaceuticals (INM) Finished Goods (2022 - 2025)

InMed Pharmaceuticals has reported Finished Goods for 4 years, with the latest figure at $378636.0 in Q4 2025.

• On a quarterly basis, Finished Goods fell 43.92% year-over-year to $378636.0 in Q4 2025; TTM through Dec 2025 was $378636.0, a 43.92% decrease from a year earlier, with the FY2025 full-year figure at $676178.0, down 19.58% from the prior year.
• Finished Goods was $378636.0 for Q4 2025 at InMed Pharmaceuticals, up from $295809.0 in the prior quarter.
• The five-year high for Finished Goods was $927182.0 in Q3 2024, with the low at $231956.0 in Q1 2025.
• Average Finished Goods over 4 years is $596273.0, with a median of $582161.0 recorded in 2022.
• The sharpest annual moves came in 2023 and 2025: Finished Goods soared 88.73% in 2023, then slumped 68.1% in 2025.
• Over 4 years, Finished Goods stood at $605956.0 in 2022, then declined by 7.94% to $557859.0 in 2023, then grew by 21.03% to $675164.0 in 2024, then plunged by 43.92% to $378636.0 in 2025.
• The last three Finished Goods figures came in at $378636.0 (Q4 2025), $295809.0 (Q3 2025), and $676178.0 (Q2 2025), per Business Quant data.